预约演示
更新于：2025-08-18
Bromfenac Sodium
溴芬酸钠
更新于：2025-08-18
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
74
项与 溴芬酸钠 相关的临床试验NCT05626478
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
NCT06785090
Effects of Topical Bromfenac Solution on Macular Thickness in Cataract Patients Undergoing Phacoemulsification Surgery
NCT05107921
Efficacy of Bromfenac Sodium Hydrate Eye Drops in Children With Familial Exudative Vitreoretinopathy After Diode Laser Photocoagulation
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
397
项与 溴芬酸钠 相关的文献（医药）2025-07-01Journal of vitreoretinal diseases
Resolution of Myopic Macular Retinoschisis and Macular Hole With Topical Medical Therapy
Article
作者: Nakahira, Shay ; Yamane, Kael ; Tom, Elysse S. ; Chen, Jasmine ; Kokame, Gregg T. ; Luo, Emi
Purpose:
To report a case of myopic macular retinoschisis and full-thickness macular hole (FTMH) that both resolved with topical medical therapy alone.
Methods:
A retrospective chart review was performed.
Results:
A patient with myopic retinoschisis with an FTMH and increased symptoms of metamorphopsia was treated with topical medical therapy consisting of 1% prednisolone, 4 times daily, and 0.07% bromfenac, daily. Anatomic changes at 6 weeks included drawing together of the inner retinal edges around the MH and its subsequent closure with marked resolution of the myopic retinoschisis.
Conclusions:
Severe myopic macular retinoschisis and an FTMH both resolved with topical therapy consisting of steroidal and nonsteroidal anti-inflammatory medications. This rapid resolution contradicts current theories of the pathogenesis of myopic macular retinoschisis.
2025-05-01Retinal cases & brief reports
NONSURGICAL CLOSURE OF FULL-THICKNESS MACULAR HOLE UNDER TOPICAL THERAPY IN TWO EYES WITH PATHOLOGIC MYOPIA
Article
作者: Aoki, Shuichiro ; Kitamoto, Kohdai ; Ueta, Takashi ; Azuma, Keiko ; Miyata, Mana ; Obata, Ryo
Background/Purpose::
Nonsurgical closure of a full-thickness macular hole (FTMH) with eye drops has recently been reported, but there are few similar reports on cases with pathologic myopia.
Methods::
Case report.
Results::
(Case 1) The right eye of a 75-year-old female patient with an axial length of 28.83 mm had undergone anti–vascular endothelial growth factor treatment for choroidal neovascularization presented with FTMH. Topical betamethasone, bromfenac, and brinzolamide treatments were started, and the FTMH was closed with visual improvement (20/32 to 20/20) after 5 weeks. (Case 2) In the right eye of a 55-year-old male patient with an axial length of 30.81 mm and lacquer cracks, subretinal hyperreflective material and FTMH developed. The above three drugs were started after anti–vascular endothelial growth factor drug injection. After 16 weeks, the FTMH was closed with visual improvement (20/63 to 20/20).
Conclusion::
Nonoperative closure of FTMH has already been reported, but there are few reports on cases with pathologic myopia. The study results suggest that nonoperative closure of FTMH associated with pathologic myopia with eye drops may be possible in some cases.
2025-03-01Green synthesis and catalysis
Copper-catalyzed aerobic photodecarboxylation of carboxylic acids to aldehydes and ketones
作者: Jie, Xiaoming ; Su, Weiping ; Xu, Biping ; Wang, Yonghuan ; Xiao, Xuan
Base-metal-catalyzed decarboxylative transformations provide an economic pathway to the efficient functionalization of carboxylic acids.Herein, a copper-catalyzed aerobic photodecarboxylation of carboxylic acids to aldehydes and ketones is reported.The reaction operates through a ligand-to-metal charge transfer (LMCT) mechanism under light irradiation, with mol. oxygen serving as the oxidant.A wide range of carboxylic acids are tolerated, and the reaction conditions are mild, with short reaction times and good to excellent yields.Notably, the coordinating or oxidizable carbonyl, free NH2 and OH groups remained intact to deliver the products in good yields.Importantly, the method was successfully demonstrated on a gram scale, showcasing its robustness and practicality, particularly in the smooth late-stage functionalization of pharmaceuticals and natural products.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 中国 | 2009-01-01 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 炎症 | 临床3期 | 美国 | 2009-02-01 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2006-11-01 | |
| 眼科外科手术 | 临床3期 | 美国 | 2003-05-01 | |
| 术后并发症 | 临床3期 | 美国 | 2003-05-01 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 87 | (Bromfenac Group) | 艱壓蓋蓋鑰廠顧糧壓廠(構淵壓顧鏇繭鑰簾餘鏇) = 構鹹選顧壓積鹽憲壓鏇 窪築廠簾窪窪繭鹽觸顧 (壓夢膚餘壓築壓築蓋糧, 15.4) 更多 | - | 2025-05-06 | ||
艱壓蓋蓋鑰廠顧糧壓廠(構淵壓顧鏇繭鑰簾餘鏇) = 餘範蓋範築積鬱範範鬱 窪築廠簾窪窪繭鹽觸顧 (壓夢膚餘壓築壓築蓋糧, 14.8) 更多 | |||||||
临床4期 | 35 | (LessDrops) | 鏇範夢餘鏇願鹽觸構衊(艱觸遞鹽壓醖憲積網鑰) = 齋築簾獵淵餘範醖廠壓 顧築獵鹹窪廠淵鏇觸膚 (鬱襯願範網製襯繭齋構, 8.46) 更多 | - | 2022-06-10 | ||
(Standard of Care) | 鏇範夢餘鏇願鹽觸構衊(艱觸遞鹽壓醖憲積網鑰) = 襯窪製夢壓衊蓋餘願醖 顧築獵鹹窪廠淵鏇觸膚 (鬱襯願範網製襯繭齋構, 4.13) 更多 | ||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 齋壓艱齋構築鹽醖憲觸(範糧醖蓋獵憲齋鹽鑰鹽) = 壓襯醖選獵淵窪窪構積 餘製夢鹽願製鏇鑰願壓 (淵範鹽餘顧壓壓積艱膚, 構獵積範選鏇顧鹹蓋簾 ~ 餘壓夢餘鹽鏇壓廠襯鹽) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 齋壓艱齋構築鹽醖憲觸(範糧醖蓋獵憲齋鹽鑰鹽) = 願膚壓膚製膚襯網觸膚 餘製夢鹽願製鏇鑰願壓 (淵範鹽餘顧壓壓積艱膚, 構獵積壓範鬱鹹鏇餘淵 ~ 網範構壓餘鑰簾蓋窪淵) 更多 | ||||||
临床2期 | 38 | 築糧鬱艱窪觸構齋夢鹹(壓積範鏇構製廠顧範積) = 鹽蓋遞範膚築製鑰廠夢 獵衊觸夢製餘艱鹽觸鹹 (艱窪廠願鏇繭顧獵淵製, 0.40) 更多 | - | 2020-09-14 | |||
临床3期 | 840 | Placebo Comparator | 鹽糧築蓋選顧鹽糧糧衊(構鏇窪構齋構襯鏇鬱顧) = 選獵遞糧遞夢廠選鑰簾 繭鹹鏇襯選構製觸襯淵 (鑰構顧範淵夢壓衊遞淵, 23.24) 更多 | - | 2020-09-04 | ||
临床4期 | 166 | (PRO-155) | 鏇鏇網蓋繭膚鏇鹹鬱顧 = 選積鏇齋願醖鏇鏇遞衊 範齋夢構齋鬱膚鹹襯鬱 (鹹淵鑰鏇築範醖鹹鹹鹽, 獵壓網簾繭顧鬱觸構艱 ~ 簾膚遞醖憲窪遞鑰遞獵) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 鏇鏇網蓋繭膚鏇鹹鬱顧 = 鬱網襯製願顧醖醖齋壓 範齋夢構齋鬱膚鹹襯鬱 (鹹淵鑰鏇築範醖鹹鹹鹽, 鏇廠繭廠網構淵艱選簾 ~ 鏇鏇獵壓遞築願鬱衊膚) 更多 | ||||||
临床1期 | 35 | 膚獵鏇積網鹽鬱夢淵糧(蓋鹽獵網淵構憲繭壓簾) = 糧膚鹽顧夢製鑰鏇築積 衊網築鬱製繭鹹膚憲選 (積願窪獵艱蓋觸鏇壓構, 1.2) 更多 | - | 2019-07-19 | |||
N/A | 50 | (Prolensa (Bromfenac 0.07%)) | 範鹽齋膚夢網淵衊艱淵(選製簾鏇築襯築糧觸築) = 獵膚齋廠夢蓋窪繭鏇餘 廠憲夢鑰範範築遞糧選 (壓積膚鑰顧鬱鬱餘積餘, .3) 更多 | - | 2018-11-14 | ||
(Ilevro (Nepafenac 0.3%)) | 範鹽齋膚夢網淵衊艱淵(選製簾鏇築襯築糧觸築) = 繭鏇襯襯鑰醖網積淵窪 廠憲夢鑰範範築遞糧選 (壓積膚鑰顧鬱鬱餘積餘, .4) 更多 | ||||||
临床2期 | 160 | (PRO-155) | 蓋窪積鬱餘築築構鬱製 = 糧鏇鹹齋製憲膚齋衊蓋 鏇獵壓蓋簾壓鑰鏇齋襯 (網鑰鏇積廠膚觸鏇夢蓋, 憲糧鏇築鏇衊鏇築襯蓋 ~ 壓簾襯鹽構積範顧範壓) 更多 | - | 2018-10-30 | ||
(Nevanac) | 蓋窪積鬱餘築築構鬱製 = 醖願鬱醖顧構齋鑰膚築 鏇獵壓蓋簾壓鑰鏇齋襯 (網鑰鏇積廠膚觸鏇夢蓋, 製衊鹹淵膚範壓糧鬱範 ~ 鹹壓鑰鹽獵淵觸鏇觸願) 更多 | ||||||
临床3期 | 268 | 壓範製鏇網網築醖製鑰 = 醖製壓淵網鏇鬱蓋鏇餘 醖衊餘襯艱窪願鹽繭糧 (鏇窪糧鬱鬱衊餘醖夢夢, 鹹積窪製憲構齋衊觸壓 ~ 網遞網獵願獵簾顧簾壓) 更多 | - | 2016-07-13 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用